Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Indications and Usage Saxenda (liraglutide) injection 3 mg is indicated in combination with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with body weight greater than 60kg and obesity Adults with overweight in the presence of at least one weight related comorbid condition Limitations of Use Saxenda contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist The safety and effectiveness of Saxenda in pediatric patients with type 2 diabetes have not been established References 1
Nature 495 , 534538 (2013)
The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis
Tirzepatide is the active ingredient in Mounjaro and Zepbound, FDA-approved for type 2 diabetes and chronic weight management
How May GIP Enhance the Therapeutic Efficacy of GLP-1
Trump Bolsters National Security and Strengthens U.S
US$ 24.86
US$ 20.59
US$ 27.30
US$ 25.38
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 23.58
US$ 25.56
US$ 27.90
